Industry Outlook and Trend Analysis
The global Cephalosporin Drugs Market has observed considerable growth in the recent years and is foreseen to encounter significant growth in the upcoming years. Cephalosporin is a bactericidal β-lactam anti-microbial, which is used to regard bacterial diseases, for example, skin infections, staph infections, pneumonia, bronchitis, gonorrhoea, tonsillitis, otitis media, and strep throat. Increment in rate of populace experiencing bronchitis, pneumonia, gonorrhoea, and tonsillitis boosts the market development. Also, increment in R&D exercises to grow profoundly proficient and safe medications and upsurge being used of mix treatments help the development of the market. Nonetheless, side effects related with cephalosporin and improvement of medication safe bacterial strains block the market development.
Drivers and Restraints
Rising number of individuals experiencing chronic diseases worldwide is the central point that boosts the market development. As per the 2016 appraisals of WHO, about one million sexually transmitted diseases (STIs) are reported each day all through the globe, representing more than 340 million new instances of sexually transmitted bacterial and protozoal contaminations in a year. Additionally, a 2016 research article expressed that urinary tract infections (UTI) are a very common bacterial diseases, which influence about 150 million individuals for each year all inclusive. Subsequently, ascend in predominance of different bacterial sicknesses build the consumer base for cephalosporin, which thus is foreseen to supplement the development of the cephalosporin drugs market.
The cephalosporin drugs market is segmented by generation, type, route of drug administration and application. Based on generation, the market is segmented into first-generation cephalosporin, second-generation cephalosporin, third-generation cephalosporin, fourth-generation cephalosporin, and fifth-generation cephalosporin. On the basis of type, it is sectioned into generics and branded. Based on route of drug administration, it is segmented into oral and injection. The applications include skin infection, respiratory tract infection, urinary tract infection, ear infection, sexually transmitted infection, and others.
Regional Outlook and Trend Analysis
Asia-Pacific is a lucrative market for cephalosporin drugs because of high populace base, existence of neglected therapeutic needs, and increment in discretionary income of individuals. Asia-Pacific is thickly populated, with India and China being the most populated nations.
The leading players in the market are Eli Lilly and Company, Lupin Limited, Sanofi, Allergan, GlaxoSmithKline, Merck & Co, Pfizer, Teva Pharmaceutical Industries, Roche Holding AG and Bristol-Myers Squibb. The market is extensively competitive with leading players investing in R&D activities, mergers and acquisitions.
The Cephalosporin Drugs Market is segmented as follows-
By Route of Drug Administration:
Urinary Tract Infection
Respiratory Tract Infection
Sexually Transmitted Infection
Rest of Europe
Rest of Asia Pacific
Rest of the World
United Arab Emirates
Some of the key questions answered by the report are:
What was the market size in 2014 and forecast from 2015 to 2023?
What will be the industry market growth from 2015 to 2023?
What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
What are the major segments leading the market growth and why?
Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?